AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $157,788 | -61.4% | 12,976 | -69.4% | 0.00% | -50.0% |
| Q2 2021 | $409,000 | -65.2% | 42,422 | -64.4% | 0.00% | -60.0% |
| Q1 2021 | $1,176,000 | -65.6% | 119,004 | -19.6% | 0.01% | -66.7% |
| Q4 2020 | $3,416,000 | +55.1% | 147,940 | -5.1% | 0.02% | +50.0% |
| Q3 2020 | $2,202,000 | -35.3% | 155,950 | -30.9% | 0.01% | -37.5% |
| Q2 2020 | $3,403,000 | +63.9% | 225,665 | +0.5% | 0.02% | +23.1% |
| Q1 2020 | $2,076,000 | +78.7% | 224,643 | +88.3% | 0.01% | +116.7% |
| Q4 2019 | $1,162,000 | +579.5% | 119,304 | +459.5% | 0.01% | +500.0% |
| Q3 2019 | $171,000 | -86.4% | 21,324 | -78.9% | 0.00% | -85.7% |
| Q2 2019 | $1,261,000 | -2.6% | 101,030 | +6.2% | 0.01% | 0.0% |
| Q1 2019 | $1,294,000 | +360.5% | 95,115 | +223.9% | 0.01% | +250.0% |
| Q4 2018 | $281,000 | -49.4% | 29,365 | -36.0% | 0.00% | -33.3% |
| Q3 2018 | $555,000 | -25.6% | 45,915 | -3.8% | 0.00% | -25.0% |
| Q2 2018 | $746,000 | +19.9% | 47,745 | +15.5% | 0.00% | 0.0% |
| Q1 2018 | $622,000 | – | 41,325 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |